EG BioMed Co., Ltd. from Taiwan is excited to announce that we are establishing a laboratory in Seattle, USA, as part of our efforts to expand into the U.S. market. We are currently preparing to apply for CLIA and Washington State medical test certifications to support our U.S. clinical trials and future FDA applications.
Our company specializes in developing innovative cancer blood test technologies, aiming to achieve early cancer detection and monitor recurrence and metastasis after treatment through simple blood draws. We believe these technologies will play a significant role in improving outcomes for cancer patients.
As we expand internationally, we look forward to collaborating with U.S. medical institutions, research teams, and other partners to drive innovation and advancement in cancer detection and monitoring.
We sincerely invite interested partners to contact us and explore potential collaboration opportunities. For more information.